14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
BELFB vs AGYS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Agilysys, Inc. (AGYS) is the stronger overall head-to-head candidate over Bel Fuse Inc (BELFB) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Options & Positioning, R&D & Supply-Chain Moat). BELFB carries a Unified Composite Score of 34.5/100 (SELL) at $216.17 (16.9x Forward P/E, 16.9% operating margin), whereas AGYS carries 50.5/100 (HOLD) at $119.68 (56.5x Forward P/E, 13.5% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BELFB vs AGYS. Trailing 12-month operating profitability (BELFB 16.9% vs AGYS 13.5%) and valuation multiples (BELFB 16.9x vs AGYS 56.5x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Software - Application value chain with $3.4B market capitalization and 13.5% operating margin.
OpEx & R&D Reinvestment50.3% of Rev ($173M)
90D Engineering Disclosures0 Published
Investor FAQ BELFB vs AGYS Key Questions & Quantitative Answers
As of Nov 17, 2026, Agilysys, Inc. (AGYS) is the stronger overall head-to-head candidate over Bel Fuse Inc (BELFB) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Options & Positioning, R&D & Supply-Chain Moat). BELFB carries a Unified Composite Score of 34.5/100 (SELL) at $216.17 (16.9x Forward P/E, 16.9% operating margin), whereas AGYS carries 50.5/100 (HOLD) at $119.68 (56.5x Forward P/E, 13.5% operating margin). Technically, BELFB sits in a Neutral phase (RSI 46.2, UNCLASSIFIED options structure) and AGYS sits in a Markup phase (RSI 54.7, CONSOLIDATION options structure).
BELFB leads the Growth & Scale pillar: BELFB posts +23.2% YoY revenue growth and +3.6% YoY earnings growth on $786M TTM revenue (39.9% gross margin, 16.9% operating margin), compared with AGYS at +17.7% YoY revenue growth and +12.2% YoY earnings growth on $344M TTM revenue (63.8% gross margin, 13.5% operating margin). On trailing 12-month operating scale, BELFB generates $786M in USD-normalized revenue versus $344M for AGYS. In operating R&D and SG&A reinvestment, BELFB deploys 23.0% of Rev ($181M) (0 90-day corporate R&D disclosures) versus 50.3% of Rev ($173M) (0 disclosures) for AGYS.
BELFB screens cheaper on headline valuation multiples. BELFB trades at 16.9x Forward P/E, 52.8x Trailing P/E, 1.25x PEG, and 4.1x EV/Revenue (20.4% EBITDA margin), whereas AGYS trades at 56.5x Forward P/E, 77.7x Trailing P/E, 2.52x PEG, and 9.6x EV/Revenue (23.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BELFB (13.0% ROE) versus AGYS (13.6% ROE) capital efficiency.
In options market volatility and institutional positioning, BELFB carries 41.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.98β · 83% Vol realized risk). By comparison, AGYS carries 55.1% implied volatility (15th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.16β · 35% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.